Compare
CDT Equity Inc. vs AEON Biopharma, Inc. vs Ernexa Therapeutics Inc. vs 60 Degrees Pharmaceuticals, Inc.
| Latest fiscal year | CDT Equity Inc. CDT | AEON Biopharma, Inc. AEON | Ernexa Therapeutics Inc. ERNA | 60 Degrees Pharmaceuticals, Inc. SXTP |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | n/a | $1.01M |
| Revenue growth (YoY) | n/a | n/a | n/a | +65.5% |
| Gross margin | n/a | n/a | n/a | 22.3% |
| Operating margin | n/a | n/a | n/a | -771.6% |
| Net margin | n/a | n/a | n/a | -732.5% |
| Net income | -$39.22M | -$39.22M | -$14.08M | -$7.37M |
| EPS (Diluted) | -$1177.89 | -$3.95 | -$2.24 | -$11.73 |
| Operating cash flow | -$15.55M | -$17.31M | -$7.02M | -$6.85M |
| Free cash flow | n/a | -$17.31M | -$7.05M | -$6.99M |
| Cash & equivalents | $1.51M | $3.01M | n/a | $1.51M |
| Total assets | $5.65M | $5.56M | $5.83M | $5.37M |
| Total liabilities | $12.82M | $60.59M | $3.43M | $1.99M |
| Shareholders' equity | -$7.17M | -$55.03M | $2.40M | $3.46M |
| Return on year-end equity | n/a | n/a | -586.6% | -212.7% |
| Shares outstanding | 92.1K | 12.11M | 7.85M | 1.16M |
Revenue, most recent five fiscal years
| Fiscal year | CDT Equity Inc. | AEON Biopharma, Inc. | Ernexa Therapeutics Inc. | 60 Degrees Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | n/a | n/a | $582.0K Ended 2024-12-31 | $1.01M Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | $68.0K Ended 2023-12-31 | $607.6K Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | $0 Ended 2022-12-31 | $253.6K Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | n/a | $223.2K Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $5.80M Ended 2020-12-31 | n/a |